Introduction Gynecologic cancers are commonly managed with chemotherapy, radiotherapy, and targeted therapies, which are effective but frequently associated with significant skin side effects. These dermatologic toxicities substantially reduce patients’ quality of life and treatment adherence, highlighting the need for a comprehensive synthesis of the latest evidence to address this clinical challenge. Methods This systematic review summarizes the most up-to-date evidence (as of 2025) regarding treatment-induced skin damage in patients with gynecologic cancers. It focuses on synthesizing data related to the clinical manifestations, subclinical changes, risk factors, and management strategies of these skin toxicities. Results Key findings include three critical areas of focus: subclinical skin damage (early, mostly asymptomatic changes induced by medications such as paclitaxel), radiotherapy-related skin issues, and severe skin effects associated with novel targeted therapies. Additionally, innovative technologies (e.g., 3D printed radiotherapy devices) were identified as potential tools for preventing and mitigating dermatologic toxicities. Discussion The review emphasizes the importance of individualized intervention plans and multidisciplinary care models to effectively manage treatment-related skin toxicities. By synthesizing the latest evidence on manifestations, mechanisms, risk factors, and innovative mitigation strategies, this review aims to provide clinicians with optimal information to improve outcomes for gynecologic cancer patients experiencing skin toxicities, thereby enhancing treatment adherence and overall patient well-being.
Wang et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: